Compound Heterozygous Frameshift Mutations in MESD Cause a Lethal Syndrome Suggestive of Osteogenesis Imperfecta Type XX
暂无分享,去创建一个
U. Kornak | H. Rehder | M. Amling | A. Kreczy | T. Schinke | J. Zustin | J. Stürznickel | R. Oheim | K. Jähn-Rickert | K. Schoner | M. M. Delsmann | Floriane Hennig
[1] S. Mundlos,et al. Clinical Phenotype and Relevance of LRP5 and LRP6 Variants in Patients With Early‐Onset Osteoporosis (EOOP) , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] D. Seelow,et al. VarFish: comprehensive DNA variant analysis for diagnostics and research , 2020, Nucleic Acids Res..
[3] M. Amling,et al. Large osteocyte lacunae in iliac crest infantile bone are not associated with impaired mineral distribution or signs of osteocytic osteolysis. , 2020, Bone.
[4] M. Amling,et al. Multiscale bone quality analysis in osteoarthritic knee joints reveal a role of the mechanosensory osteocyte network in osteophytes , 2020, Scientific Reports.
[5] D. Sillence,et al. Nosology and classification of genetic skeletal disorders: 2019 revision , 2019, American journal of medical genetics. Part A.
[6] C. Kim,et al. Autosomal Recessive Mutations in MESD Cause Osteogenesis Imperfecta. , 2019, American journal of human genetics.
[7] Daniela Hombach,et al. MutationDistiller: user-driven identification of pathogenic DNA variants , 2019, Nucleic Acids Res..
[8] P. Coucke,et al. Homozygosity for CREB3L1 premature stop codon in first case of recessive osteogenesis imperfecta associated with OASIS-deficiency to survive infancy. , 2018, Bone.
[9] A. Munnich,et al. FAM46A mutations are responsible for autosomal recessive osteogenesis imperfecta , 2018, Journal of Medical Genetics.
[10] F. Glorieux,et al. Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] S. Stewart,et al. Phenotypic Spectrum in Osteogenesis Imperfecta Due to Mutations in TMEM38B: Unraveling a Complex Cellular Defect , 2017, The Journal of clinical endocrinology and metabolism.
[12] Heeseog Kang,et al. Osteogenesis imperfecta: new genes reveal novel mechanisms in bone dysplasia. , 2017, Translational research : the journal of laboratory and clinical medicine.
[13] F. Glorieux,et al. Non-Lethal Type VIII Osteogenesis Imperfecta Has Elevated Bone Matrix Mineralization. , 2016, The Journal of clinical endocrinology and metabolism.
[14] M. Amling,et al. The Anti‐Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5 , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] D. Burr,et al. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone , 2015, Proceedings of the National Academy of Sciences.
[16] F. Rauch,et al. Hyperosteoidosis and Hypermineralization in the Same Bone: Bone Tissue Analyses in a Boy with a Homozygous BMP1 Mutation , 2013, Calcified Tissue International.
[17] J. Marini,et al. New genes in bone development: what's new in osteogenesis imperfecta. , 2013, The Journal of clinical endocrinology and metabolism.
[18] R. Gibbs,et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. , 2013, The New England journal of medicine.
[19] S. Mundlos,et al. Mutations in WNT1 cause different forms of bone fragility. , 2013, American journal of human genetics.
[20] Emily H Turner,et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. , 2013, American journal of human genetics.
[21] Wei Zhang,et al. The C-Terminal Region Mesd Peptide Mimics Full-Length Mesd and Acts as an Inhibitor of Wnt/β-Catenin Signaling in Cancer Cells , 2013, PloS one.
[22] Roland Baron,et al. WNT signaling in bone homeostasis and disease: from human mutations to treatments , 2013, Nature Medicine.
[23] J. Kanis,et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] A. Evdokiou,et al. Sclerostin is a locally acting regulator of late‐osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE‐ASARM‐dependent mechanism , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] G. Bu,et al. Two structural and functional domains of MESD required for proper folding and trafficking of LRP5/6. , 2011, Structure.
[26] Jana Marie Schwarz,et al. MutationTaster evaluates disease-causing potential of sequence alterations , 2010, Nature Methods.
[27] Yonghe Li,et al. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells. , 2010, Biochemistry.
[28] Lynda F. Bonewald,et al. Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis , 2010, Molecular and Cellular Biology.
[29] K. Ozono,et al. Lrp6 Hypomorphic Mutation Affects Bone Mass Through Bone Resorption in Mice and Impairs Interaction With Mesd , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[30] F. Glorieux,et al. Evidence that Abnormal High Bone Mineralization in Growing Children with Osteogenesis Imperfecta is not Associated with Specific Collagen Mutations , 2008, Calcified Tissue International.
[31] E. Åström. Management of osteogenesis imperfecta , 2008 .
[32] S. Blacklow,et al. Requirement for natively unstructured regions of mesoderm development candidate 2 in promoting low-density lipoprotein receptor-related protein 6 maturation. , 2007, Biochemistry.
[33] Wenyan Lu,et al. Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding , 2005, Journal of Cell Science.
[34] O. Mäkitie,et al. Heterozygous Mutations in the LDL Receptor‐Related Protein 5 (LRP5) Gene Are Associated With Primary Osteoporosis in Children , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] Hans Clevers,et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.
[36] M. Bouxsein,et al. Decreased BMD and Limb Deformities in Mice Carrying Mutations in Both Lrp5 and Lrp6 , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[37] W. Skarnes,et al. The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice , 2004, Development.
[38] R. Mann,et al. Boca‐dependent maturation of β‐propeller/EGF modules in low‐density lipoprotein receptor proteins , 2004, The EMBO journal.
[39] J. Hsieh,et al. Mesd Encodes an LRP5/6 Chaperone Essential for Specification of Mouse Embryonic Polarity , 2003, Cell.
[40] Mark L. Johnson,et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.
[41] Miikka Vikkula,et al. LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.
[42] William C. Skarnes,et al. An LDL-receptor-related protein mediates Wnt signalling in mice , 2000, Nature.
[43] L. Peltonen,et al. Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. , 1996, American journal of human genetics.
[44] T. Magnuson,et al. msd is required for mesoderm induction in mice. , 1994, Development.
[45] S. Gould. Textbook of Fetal and Perinatal Pathology , 1991 .
[46] D. Sillence,et al. Genetic heterogeneity in osteogenesis imperfecta. , 1979, Journal of medical genetics.
[47] P. Esposito,et al. Osteogenesis Imperfecta. , 1928, Proceedings of the Royal Society of Medicine.